A better approach to antibiotic development.

Arcum Therapeutics employs a systematic approach to developing the next generation of antibiotics. Rather than assumming the risks and costs associated with the conventional method of searching for new chemical entities, Arcum attacks the most dangerous bacteria by utilizing synergistic combinations of drugs already proven to be safe and effective.

This results in a faster and less expensive time to market under the FDA 505b2 accelerated pathway with a more attractive risk profile for investors.

Our Approach


Identify dangerous bacterial target

We are fighting the pathogens deemed to be the most urgent threats by the CDC


Gold standard treatment

We start with the gold standard drug that doctors know and trust


Add synergistic compound

We combine another known compound that works synergistically along our propietary RnpA pathway


Fight resistance

The resulting Arcum therapeutic has improved efficacy with lower bacterial resistance

Arcum Therapeutics

Fighting resistance to save lives.

The CDC estimates that antibiotic resistant strains of bacteria and fungus account for over 2,049,442 illnesses and 23,000 deaths annually.

Read more

Without urgent action we are heading for a post-antibiotic era, in which common infections and minor injuries can once again kill.

- World Health Organization


We are developing a platform of antibiotics to fight the most dangerous bacterial infections starting with wound, burn, and eye infections.

Each drug product is bundled into its own subsidiary, with Arcum Therapeutics acting as the parent company that retains the technology and intellectual property involved with the drug discovery process.

Arcum Therapeutics - MRSA

MRSA Wound Product

Status: Pre-Clinical Development

  • Methicillin-resistant S aureus (MRSA) can be a life threatening infection quickly leading to sepsis and death
  • Studies show 1 in 3 people carry S aureus and 2 in 100 carry MRSA 1
  • Hospital acquired MRSA infections cost hospitals $80k/patient
  • Mupirocin is the currently used gold standard topical antibiotic ($400M annual sales)
Our Product:
  • We have identified a combination drug that works along our proprietary RnpA pathway
  • This product has been shown to produce greater efficacy and lower resistance in comparison to Mupirocin
  • We have partnered this product with a leading dermatology contract research organization (CRO) and are currently developing formulations for GMP
Arcum Therapeutics - Eye drops

Bacterial Conjunctivitis/Corneal Infection Product

Status: Lead Development

  • Bacterial keratitis contributes to 2 million new cases of blindness world wide annually
  • Staphylococcus aureus and Pseudomonas aeruginosa are the predominant causes of bacterial keratitis
  • Current treatment regiments are failing due to resistance
Our Product:
  • We have developed a proprietary drug combination that displays synergistic and rapid bactericidal activity toward S. aureus and P. aeruginosa
  • The combination exhibits exquisite activity toward biofilms, a unique bacterial growth state that is believed to contribute to keratitis
  • The combination’s performance equals or exceeds current front-line keratitis therapeutics, but does not suffer from resistance liabilities
Arcum Therapeutics - Efflux Pump

Burn Wound Product

Status: Lead Development

  • Burn site infections increase patient mortality by 5% 2, 3
  • The ESKAPE bacterial pathogens account for approximately 57% of burn wound infections 4, 5
  • One of the most common preparations of medicinal silver, silver sulfadiazine, is the active component of numerous wound care-associated products, including burn wound ointments, creams, and bandages as well as coatings on indwelling catheters. 6, 7, 8
  • Numerous clinical studies have called into question the therapeutic impact of silver sulfadiazine treatment.
Our Product:
  • We have developed a proprietary drug combination the displays synergistic antimicrobial activity toward the ESKAPE pathogens
  • The combination displays improved efficacy toward the ESKAPEs in animal models representative of burn wound infections

© 2017 Arcum Therapeutics.